2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
02:00 p.m. - 03:30 p.m.
MCCNO - New Orleans Theatre A
Treatment Considerations, Drug Development, Therapy Sequence, Biological Therapies, Transplantation, (CAR)-T Cell Therapies, Adverse Events, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Non-Hodgkin Lymphoma, B Cell Lymphoma, Research, Clinical Research, Clinical Trials, Real-World Evidence
PAPER

235 Real-world outcomes of CAR T-cell therapy versus allogeneic hematopoietic cell transplantation in relapsed and refractory mantle cell lymphoma: A retrospective study of the lymphoma working party of the EBMT

Nora Liebers, MD, Maud Ngoya2, Susanne Anna Christine Schmidt3, Katherine Clesham4, Stefania Bramanti, MD5, Carin Hazenberg6, Francesca Bonifazi7, Gerald Wulf8, Rachel Protheroe9, Urban Novak10, Sridhar Chaganti11, Anne Huynh12, Victoria Potter13, Vladan Vucinic, MD14, Didier Blaise, MD15, Igor Wolfgang Blau16, Simona Sica17, Olivier Hermine, MD, PhD18, Peter Dreger, Prof. Dr. med.19, Bertram Glass, MD20, Sascha Dietrich21, Ali Bazarbachi22
1 Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf (CIO ABCD), Aachen Bonn Cologne Duesseldorf, Germany, University Hospital Duesseldorf, Duesseldorf, Germany
2 European Society for Blood and Marrow Transplantation, Paris, France
3 Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf (CIO ABCD), Aachen Bonn Cologne Duesseldorf, Germany, University Hospital Duesseldorf, Duesseldorf, Germany
4 University College London Hospitals NHS Trust, London, United Kingdom
5 IRCCS Humanitas Research Hospital, Humanitas, Cancer Center, Milano, Italy
6 University Medical Center Groningen, University of Groningen, Groningen, Netherlands
7 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
8 University Medical Center Göttingen, Göttingen, Germany
9 University Hospitals Bristol and Weston NHSFT, Bristol, United Kingdom
10 Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland
11 Birmingham Centre for Cellular Therapy and Transplant (BCCTT), Stoke, Birmingham, United Kingdom
12 CHU - Institut Universitaire du Cancer Toulouse, Toulouse, France
13 Kings College Hospital London, London, United Kingdom
14 University Hospital Leipzig, Leipzig, Germany
15 Institut Paoli Calmettes, Aix Marseille Université, Marseille, France
16 Charite Berlin, Berlin, Germany
17 Dipartimento di Scienze di Laboratorio ed Ematologiche-Fondazione Policlinico Universitario Agostino Gemelli-IRCCS, Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Roma, Italy
18 European Society for Blood and Marrow Transplantation, Paris, France, Service d'Hématologie Adultes, Institut Necker Enfants Malades, Unité INSERM U1153, Hôpital Universitaire Necker-Enfants Malades, AP-HP, Université Paris Cité and Imagine Institute, Paris, France
19 European Society for Blood and Marrow Transplantation, Paris, France, Heidelberg University Hospital, Heidelberg, Germany
20 European Society for Blood and Marrow Transplantation, Paris, France, Helios Clinic Berlin-Buch, Berlin, Germany
21 Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf (CIO ABCD), Aachen Bonn Cologne Duesseldorf, Germany, European Society for Blood and Marrow Transplantation, Paris, France, University Hospital Duesseldorf, Duesseldorf, Germany
22 American University of Beirut, Beirut, Lebanon, European Society for Blood and Marrow Transplantation, Paris, France

Introduction

CD19-directed CAR T-cell therapy has transformed the treatment landscape of relapsed/refractory (r/r) mantle cell lymphoma (MCL) and become the preferred cellular treatment. However, global access to CAR T-cell therapy remains heterogeneous, whereas allogeneic hematopoietic cell transplantation (alloHCT) is more broadly established across healthcare systems. This European Society for Blood and Marrow Transplantation (EBMT) analysis provides real-world comparative outcome data for CAR T-cell therapy and alloHCT in an international cohort of 1029 patients with r/r MCL treated in the CAR T-cell era.

 

Methods

We performed a retrospective analysis of patients aged ≥18 years with MCL who underwent a first CAR T-cell therapy or a first alloHCT >12 months after initial diagnosis between 2019 and 2024 and were reported to the EBMT registry.

Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method, while cumulative incidence functions were applied in a competing risk setting for non-relapse mortality (NRM) and relapse incidence (RI). In a subgroup analysis, propensity scores were used for 1:1 nearest-neighbor matching without replacement, balancing for four baseline characteristics: age, Karnofsky performance status at the time of cellular therapy, interval from diagnosis to cellular therapy, and disease status at the time of cellular therapy.

 

Results

A total of 626 patients treated with CAR T-cell therapy and 403 patients treated with alloHCT were identified in the EBMT registry. Patients receiving CAR T-cell therapy were significantly older at the time of treatment than those undergoing alloHCT (median 67.7 vs 59.7 years, p<0.001), and more frequently had a Karnofsky performance status <90 (36.2% vs 19.6%, p<0.001). The median interval from initial diagnosis to cellular therapy was 58.8 months (IQR, 28.1-103.2) in the CAR T-cell cohort and 51.4 months (IQR, 30.2-77.9) in the alloHCT cohort. At the time of cellular therapy, 62.1% of patients in the CAR T-cell cohort had progressive disease, whereas most patients in the alloHCT cohort underwent transplantation with disease control (CR, 67%; PR, 24.6%). Brexucabtagene autoleucel was the predominant CAR T-cell product (98.4%). Among alloHCT recipients, 76.1% received reduced-intensity conditioning (RIC), and 62.4% underwent transplantation from an unrelated donor.

The median follow-up was 1.5 years (95% confidence interval [CI], 1.3-1.8) in the CAR T-cell cohort and 3.3 years (95% CI, 3.0-3.7) in the alloHCT cohort. At 2 years, OS was 61% and 59.1%, while PFS was 54.4% and 46.3% for the CAR T-cell and alloHCT cohorts, respectively. Corresponding 2-year NRM rates were 21.5% and 27.1%, whereas RI was 24.1% and 26.6%, respectively.

To account for baseline imbalances, a propensity score-matched subgroup analysis of 122 patients per cohort was performed. After matching, the median age at cellular therapy was 63.6 years, 28.7% of patients had a Karnofsky performance status <90, and disease status at the time of cellular therapy was more balanced, with 35.2% and 23.8% of patients having progressive disease in the CAR T-cell and alloHCT cohorts, respectively. In the matched cohort, CAR T-cell therapy was associated with significantly superior 2-year OS (66.2% vs 49.6%, hazard ratio [HR], 0.64 (95% CI, 0.42-0.97), p=0.03) and PFS (59% vs 39.9%, HR, 0.62 (95% CI, 0.42-0.92), p=0.02). Notably, this was accompanied by a significantly lower 2-year NRM after CAR T-cell therapy (12.7% vs 29.4%, HR, 0.39 (95% CI, 0.2-0.76), p=0.005) whereas no significant difference was observed for RI (28.3% vs 30.7%, HR, 0.85 (95% CI, 0.5-1.44), p=0.54).

 

Conclusions

This large EBMT analysis supports CAR T-cell therapy as the preferred first cellular therapy for patients with r/r MCL, owing to its applicability across a broader range of patients, superior survival outcomes, and lower NRM. AlloHCT remains a valuable treatment option, particularly in healthcare settings with limited access to CAR T-cell therapy and for patients in whom CAR-T cell therapy has failed.

Sascha Dietrich: No relevant conflicts of interest to declare.